FDA Chief to Depart After Trump Signed Off on Ousting Him
FDA chief to depart after Trump – Marty Makary, the head of the Food and Drug Administration, is set to resign following President Donald Trump’s approval of a plan to replace him. Three sources close to the situation confirmed the decision, which was finalized last week. Makary’s departure marks another shift in the administration’s health leadership, as he had been a prominent figure since his confirmation in March 2025. His exit comes amid mounting tensions within the Trump team and external pressures from industry groups and advocacy organizations.
Internal and External Pressures Converge
The FDA chief faced significant challenges both from within and outside the administration. His resistance to approving flavored e-cigarettes, particularly those targeting youth, became a focal point of criticism. This decision sparked direct confrontation with Trump, who had grown frustrated with the agency’s stance. Additionally, Makary’s leadership was scrutinized for frequent staff changes in senior roles, leading to instability and internal discord. The pharmaceutical sector, along with anti-abortion groups, voiced concerns over his policies, further complicating his position.
As the FDA’s leader, Makary had promised to streamline decision-making on drugs, devices, and vaccines. However, his tenure saw him entangled in multiple controversies. Pharmaceutical companies criticized his management of the drug approval process, while administration officials questioned his handling of broader regulatory issues, such as tobacco policies. The recent focus on flavored e-cigarettes intensified these tensions, culminating in Trump’s endorsement of his removal.
“He doesn’t want to approve youth-appealing flavors, but has been forced to by the powers that be,” said a source close to Makary’s departure.
Makary’s resignation also coincides with a critical moment in his career. He was scheduled to testify before the Senate Appropriations Committee regarding the FDA’s proposed budget just one day prior. The timing of his exit has raised questions about the administration’s strategic priorities and the role of political considerations in regulatory decisions.
Replacing the FDA Chief
Trump is expected to appoint Kyle Diamantas, currently the deputy commissioner overseeing the agency’s food program, as the acting FDA head. Diamantas, a seasoned official, is likely to maintain continuity while the administration seeks a permanent replacement. However, the process will require Senate confirmation, adding another layer of complexity to the health department’s leadership.
The FDA’s leadership transition highlights the administration’s ongoing efforts to consolidate control over key regulatory agencies. With Makary’s departure, Trump will need to fill a vacancy in the top ranks of the U.S. Health and Human Services Department. This follows the absence of a permanent CDC director and surgeon general, both of whom are traditionally seen as critical to public health policy. The lack of stable leadership has been a recurring issue, with the administration struggling to maintain consistency in its approach to health regulations.
Political Motivations Behind the Move
While some Trump aides initially hesitated to remove Makary, fearing a political misstep, others viewed the change as necessary. The “Make America Healthy Again” base, a key voter demographic, had grown increasingly wary of the FDA’s perceived indecision. By ousting Makary, the administration aims to reassert its influence and align the agency with its agenda, particularly in areas like reproductive rights and drug access.
The push for Makary’s resignation accelerated in recent days, driven by a faction of White House and HHS officials who grew disillusioned with the FDA’s operations. They argued that the agency had become a source of chaos, with conflicting policies and leadership instability. The decision to replace Makary is seen as a calculated move to reset the FDA’s direction and strengthen relationships with key stakeholders, including the anti-abortion movement and pharmaceutical industry.
One recent incident that fueled the push was Makary’s reluctance to approve fruit-flavored e-cigarettes. This resistance led to a direct confrontation with Trump, who reportedly pressed him on the issue. Despite this, the FDA reversed its position last week, indicating that pressure from within the administration had successfully shifted its stance. Another notable event involved Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, who met with White House officials to advocate for changes to mifepristone regulations. Mifepristone, a drug used for medication abortions, is now responsible for about two-thirds of all U.S. abortions, making its regulation a critical point of contention.
Broader Implications for Health Policy
Makary’s resignation underscores the dynamic nature of leadership in the Trump administration. While his departure may streamline the FDA’s operations, it also signals a shift toward more politically aligned decision-making. The agency’s restructuring, including potential changes to its senior staff, is expected to reflect these new priorities. With a new acting chief in place, the focus will turn to selecting a permanent replacement, a process that could take weeks or months.
The administration’s approach to health policy has been marked by rapid changes and ideological alignment. Makary’s emphasis on accelerating FDA decisions was overshadowed by his stance on flavored e-cigarettes and mifepristone. His removal is part of a broader strategy to align the FDA with Trump’s vision, particularly in issues that resonate with the president’s core supporters. This includes policies that restrict access to abortion medications and prioritize regulatory decisions that reflect conservative values.
As the HHS department continues to grapple with leadership gaps, the stakes for the upcoming midterms are evident. The Senate’s role in confirming new appointments adds urgency to the process. With Makary’s resignation, the administration is now tasked with not only filling the FDA chief vacancy but also addressing other critical positions, such as the surgeon general and CDC director. These roles are vital to shaping public health initiatives and maintaining institutional stability.
While Makary’s exit may be seen as a victory for political actors within the administration, it also raises questions about the balance between scientific expertise and policy alignment. His resignation marks the end of an era for the FDA, but it opens the door for new leadership that may reshape the agency’s priorities. The next phase of this transition will depend on how quickly the administration can secure Senate approval and restore coherence to its health policy agenda.
Legacy of a Controversial Tenure
Makary’s time at the FDA was defined by his efforts to modernize regulatory processes and improve public health outcomes. However, his resistance to certain policies, such as the approval of flavored e-cigarettes, highlighted the tension between his scientific background and the administration’s political goals. His departure leaves a legacy of both achievements and challenges, with the FDA now under new management to navigate these complexities.
As the administration moves forward, the focus will remain on consolidating control over the health sector. The replacement of Makary is part of a larger pattern of leadership changes aimed at aligning the HHS department with the president’s priorities. With the upcoming Senate confirmation process, the future of the FDA’s direction will be shaped by the next chief, who will need to balance regulatory efficiency with political considerations.
The decision to oust Makary reflects the administration’s willingness to prioritize ideological alignment over bureaucratic continuity. While some within the team argued for a more measured approach, others saw the need for swift action to address growing dissatisfaction. This transition highlights the evolving landscape of health policy under the Trump administration, where leadership changes are often driven by a combination of internal dynamics and external pressures.
